Genrix Bio announced that its investigational product GR2302 injection has received approval for its clinical trial application. GR2302 injection is a bispecific antibody independently developed by the company, based on a TCR-mimic antibody and an anti-CD3 antibody. As of the announcement date, no drugs targeting the same target have been approved for clinical trials in China. In the first quarter of 2026, Genrix Bio achieved revenue of 67.25 million yuan and a net loss attributable to the parent company of 149 million yuan.
Chongqing Genrix Biopharmaceutical Co. Ltd. AGR2302 injection received clinical trial approval, a positive regulatory milestone for the company's pipeline.
